Business Wire

FAW Teams up with RoboSense on The World’s First Automotive-grade Solid-state Smart LiDAR Sensor for Serial Production

27.9.2019 18:00:00 EEST | Business Wire | Press release

Share

RoboSense, the pioneering Smart LiDAR Sensor provider, announced a partnership with FAW ("First Automobile Works"), the world's leading automotive OEM (Original Equipment Manufacturer), and showcased the milestone achievement of last year’s cooperation: the first batch of world’s first solid-state Smart LiDAR Sensor RS-LiDAR-M1 on September 25. The deal is to include RS-LiDAR-M1 as core component into FAW's proprietary next-generation autonomous driving system development, therefore accelerating the serial production of the world's first automotive-grade solid-state MEMS-based Smart LiDAR Sensor, in order to promote Level 3 vehicle autonomy and above.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190927005229/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FAW Teams up with RoboSense on The World’s First Automotive-grade Solid-state Smart LiDAR Sensor for Serial Production (Photo: Business Wire)

The final commercialized version of RS-LiDAR-M1 is the world’s first and only all-in-one unit MEMS-based Smart LiDAR Sensor for self-driving passenger vehicles with its own embedded AI algorithm technologies and SoC (System of Chip). It transforms traditional LiDAR systems (also known as solely data collectors), to full data analysis and comprehension systems. The RS-LiDAR-M1 not only collects and interprets high definition 3D point cloud data, but its built-in AI algorithm and SoC also process road data in real-time, while at the same time synchronizing outputs of high-precision localization, obstacle detection, tracking and classification, road curbs and driving areas detection.

Unlike RoboSense Smart LiDAR Sensor, when mechanical LiDAR is used on a vehicle, a computer-sized ECU must also be used to operate the algorithms. Compared with ECUs, the RoboSense dedicated SoC built into the Smart LiDAR Sensor not only withstands strong bumps and jolts in the vehicle, but is also small and light-weight. The RoboSense Smart LiDAR Sensor's built-in SoC can largely reduce more power consumption while improving performance compared to automotive ECUs, saving much more passenger space at the same time.

The RS-LiDAR-M1 is cleanly designed in a streamlined body that allows it to be easily embedded onto any part of the vehicle for the complete aesthetics of automobile.

Serial produced RoboSense Smart LiDAR Sensor costs only hundreds of dollars each, based on its deployment of revolutionary MEMS micro-mirror scanning structure and simplified manufacturing and streamlines production, while maintaining high product quality and reliability to meet exacting OEM requirements.

Fengjun Li, Director of Intelligent Connected Vehicle Development Institute, FAW, said, "China is standing at the front of the world's autonomous driving development. Our cooperation with RoboSense demonstrates our confidence in Smart LiDAR Sensor for Level 3 vehicle autonomy and above, and accelerates the commercialized development of our proprietary next-generation autonomous driving system”.

"The RS-LiDAR-M1 is a revolutionary product developed upon more than ten years of research development accumulated by the RoboSense team. We believe the partnership will enhance the serial production ability of automotive-grade Smart LiDAR Sensor for autonomous driving,” said Steven Qiu ChuanXin, RoboSense Founder and CEO.

At the signing ceremony, the closest to commercialized version of Smart LiDAR Sensor RS-LiDAR-M1 delivered by RoboSense will be used for FAW's automotive-grade testing and self-driving passenger cars research development. The current version has greatly improved performance while reducing the size to only the half of the former demo showcased on CES 2019, which can be easily integrated into any part of the vehicle body. More details of the latest version will be coming soon.

About RoboSense:

Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the first and only MEMS-based Smart LiDAR Sensor for autonomous driving.

For more information about RoboSense please visit: https://www.robosense.ai/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Cassie Gong, PR Manager
sqgong@robosense.cn

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye